您当前的位置: 首页 > 资源详情

Medicalxpress,10月11日,Vaccines prevent severe COVID, even from Delta: study

编译者:YUTING发布时间:Oct 15, 2021点击量:46 来源栏目:最新研究

Vaccination is highly effective at preventing severe cases of COVID-19, even against the Delta variant, a vast study in France has shown.

The research published Monday—focusing on prevention of severe COVID and death, not infection—looked at 22 million people over 50 and found those who had received jabs were 90 percent less likely to be hospitalised or die.

The results confirm observations from the US, the UK and Israel, but researchers say it is the largest study of its kind so far.

Looking at data collected starting in December 2020, when France launched its jab campaign, the researchers compared the outcomes of 11 million vaccinated people with 11 million unvaccinated subjects.

They formed pairs matching an unvaccinated individual with a vaccinated counterpart from the same region and of the same age and sex, tracking them from the date of the vaccinated person's second jab to July 20.

Starting 14 days after a second dose, a vaccinated subjects' risk of severe COVID was reduced by 90 percent, according to the research conducted by Epi-Phare, an independent medicines safety research group that works closes with the French government.

Vaccination appears to be nearly as effective against for the Delta variant, with 84 percent protection for people 75 and older and 92 percent for people 50-75.

That estimate, however, is only based on a month of data, since the variant became dominant in France only in June.

"The study should be followed up to include results from August and September," epidemiologist Mahmoud Zureik, the head of Epi-Phare, told AFP.

The study covers vaccination with the Pfizer/BioNtech, Moderna and AstraZeneca jabs, but not Jannsen which was authorised much later and is far less widely used in France.

The results also suggest that over the period of study—up to five months—vaccination protection against severe COVID did not diminish.

提供服务:导出本资源
  1. 1 Nature,11月10日,Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility
  2. 2 11月10日_研究人员分析宿主基因对COVID-19严重程度和易感性的影响
  3. 3 11月11日_新冠药物Remestemcel-L二期临床的中期分析结果积极
  4. 4 11月11日_CDC呼吁制定通用口罩规定以减少新冠传播
  5. 5 SSRN,2月20日,Dynamics of the Latest 2019 Novel Coronavirus Disease Epidemic in China: A Descriptive Study
  6. 6 SSRN,2月20日,Mental Health Problems and Social Media Exposure During COVID-19 Outbreak
  7. 7 SSRN,2月20日,Evaluating Incidence and Impact Estimates of the Coronavirus Outbreak from Official and Non-Official Chinese Data Sources
  8. 8 SSRN,2月20日,Clinical Characteristics and Treatment of Patients Infected with COVID-19 in Shishou, China
  9. 9 Nature,11月10日,Mobility network models of COVID-19 explain inequities and inform reopening
  10. 10 1月27日_Nature报道中国新型冠状病毒最新研究进展:病毒传播速度有多快?
  1. 1 11月22日_感染无害冠状病毒可增强针对SARS-CoV-2的免疫力
  2. 2 Medicalxpress,11月22日,Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape
  3. 3 11月22日_科学家开发出一种可同时测量针对SARS-CoV-2的 T细胞和抗体反应的方法
  4. 4 Medicalxpress,11月22日,Pfizer says COVID shot 100% effective in adolescents after 4 months
  5. 5 11月18日_传播性增强和/或部分免疫逃逸的SARS-CoV-2变体对人群的影响
  6. 6 11月22日_辉瑞的COVID-19疫苗在接种4个月后对青少年的有效率为100%
  7. 7 Medicalxpress,11月18日,Simple, synthetic structure that mimics surface of SARS-CoV-2 mounts robust immune response in mice
  8. 8 11月18日_模拟SARS-CoV-2表面的简单合成结构在小鼠体内引发强大的免疫反应
  9. 9 11月17日_Zosano宣布在其微针贴片系统上成功配制COVID-19候选疫苗
  10. 10 11月18日_新分析预测疫苗针对SARS-CoV-2的保护作用

版权所有@2017中国科学院文献情报中心

制作维护:中国科学院文献情报中心信息系统部地址:北京中关村北四环西路33号邮政编号:100190